Bosses Bet Big on Ozempic

Stethoscope and medication on a folder labeled FDA — OZEMPIC BOMBSHELL NEWS

A new economic study says modern weight-loss drugs are not just shrinking waistlines, they are shrinking long-term sick leave by about one-sixth.

Story Snapshot

Researchers found a 17.3% drop in long-term sick leave after workers start GLP-1 treatment.
The study ties that drop to fewer medically certified absences lasting more than 30 days.
Estimated savings equal about 1.3% to 1.5% of a worker’s annual income.
Employers are eyeing GLP-1 coverage as a possible tool to cut both health and productivity costs.

GLP-1 drugs are now a workplace story, not just a weight-loss fad

Researchers from the University of Copenhagen, the University of Chicago, Duke University, and the Rockwool Foundation dug into nationwide Danish data to answer a simple question: do GLP-1 drugs change how much people miss work?

They matched workers who started GLP-1 treatment with similar workers who did not, and then tracked medically certified sick leave over four years. Long-term sick leave meant any illness-related absence that lasted more than 30 days.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

The headline finding is blunt. After GLP-1 treatment starts, long-term sick leave drops by 0.95 percentage points from a baseline of 5.5%, which equals a 17.3% decline.

That effect is not a one-time blip. It grows over time, from about 0.8 percentage points in the first two years to 1.1 percentage points in years three and four. In plain terms, workers on these drugs spend less time on prolonged sick leave and more time on the job.

The money trail: smaller sick leave checks and real fiscal savings

The study does not stop at counting days. It follows the money. Using Danish municipal payment records, the authors estimate that Ozempic, one of the main GLP-1 brands, cuts quarterly sickness leave payments by about 19.4% compared with pre-treatment levels.

When they roll those numbers up across a year, they find combined employer and public savings of around 1.3% to 1.5% of annual earned income per treated worker, or roughly 866 dollars.

Those figures land in a long-running debate in workplace health economics. Earlier research shows that health-related productivity losses often cost employers more than direct medical and pharmacy bills, sometimes more than double.

Chronic conditions like obesity, anxiety, arthritis, and back pain are big drivers of missed work and reduced performance. When you put that backdrop next to a drug class that can improve weight, blood sugar, and heart risk factors, it makes sense that employers are paying attention.

How GLP-1 medicines might help workers stay on the job

GLP-1 medicines work by mimicking a hormone that helps control blood sugar and appetite. They prompt the body to release more insulin, lower blood sugar, and send “fullness” signals to the brain, which often leads to less eating and steady weight loss.

Beyond weight, long-term trials show reduced rates of stroke, heart failure, diabetic kidney disease, and even lower overall mortality compared with placebo. These are exactly the kinds of problems that push workers into long absences and disability.

The Danish study’s data fit that clinical story. Workers on GLP-1 therapy had fewer emergency department visits, lower use of cardiovascular drugs, and less reliance on long-term sickness benefits.

When people have fewer serious episodes and better control of chronic disease, they are less likely to tip over into month-long sick spells. For employers worried about both absenteeism and “presenteeism” — showing up sick and working at half speed — that is a tempting promise.

What this means for employers and taxpayers

Employers now face a hard choice. GLP-1 drugs are expensive, and no federal law forces health plans to cover them for obesity. But early cost studies show that for people with type 2 diabetes, medical cost growth is several percentage points lower in GLP-1 users, especially when adherence is high.

Add a documented 17.3% drop in long-term sick leave and fiscal savings around 1.5% of income, and the old idea that “health is a cost center” starts to look outdated.

The logic is straightforward. If a private drug choice cuts publicly funded sickness payments and keeps more people working, that supports self-reliance and trims the welfare state at the same time.

The Danish estimates tie GLP-1 use to lower municipal outlays for sick leave and less time on publicly supported benefits. That kind of result aligns well with policies that reward work, reduce dependency, and let markets sort out which treatments deliver value.

Loose ends: side effects, long-term use, and hype vs. reality

Any sober look needs caveats. GLP-1 medicines can cause nausea, vomiting, diarrhea, and abdominal pain, along with rarer problems tied to the pancreas, kidneys, or gallbladder.

People who stop the drugs often regain much of the weight they lost, which hints that benefits fade without long-term use. Not every worker will tolerate these medicines, and some may even need sick leave for side effects.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

The Danish study is also observational, not a randomized trial. It shows a strong association between GLP-1 use and lower long-term sick leave, but life is messy. Other factors could play small roles.

Still, the pattern fits a broader line of evidence: when treatments truly improve chronic conditions, productivity often improves too, even if the media headlines get ahead of the fine print. For now, one thing is clear. The GLP-1 story has moved firmly from the bathroom scale to the payroll ledger.